Wednesday, Jan 3, 1996

FDA Grants Genentech Clearance to Market Nutropin AQ

South San Francisco, Calif. -- January 3, 1996 --

Genentech, Inc. (NYSE:GNE) today announced that it received clearance from the U.S. Food and Drug Administration (FDA) to market Nutropin AQ™ (somatropin [rDNA origin] injection), the first and only liquid (aqueous) recombinant human growth hormone product available. Nutropin AQ has the same indications as Nutropin® (somatropin [rDNA origin] for injection), which Genentech currently markets.

Genentech, Inc. is a leading biotechnology company that discovers, develops, manufactures, and markets human pharmaceuticals for significant unmet medical needs. The Company has headquarters in South San Francisco and is traded on the New York and Pacific stock exchanges under the symbol GNE.

# # #